B+
Bull case
25%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-06-18 · RankAlpha Sentiment Codex
ZNTL
ZentalisCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is that May 2026 company disclosures showed tangible forward progress: pivotal dose selection for azenosertib, ASPENOVA initiation, and runway into late 2027, which together keep the accelerated-approval thesis alive ahead of the DENALI readout [#SEC-8K-2026-05-12].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -2.6.
What can break
Clinical readout risk is dominant because DENALI Part 2 remains the main binary value event for azenosertib.
Momentum
10
Value
41
Sentiment
71
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.50 · Bull $6.50 · Bear $1.80Analysis 2026-06-18; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-08 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-08
Investment thesis
As of 2026-09-08
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-08. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $7.30
Why
Momentum10 · Δ7d -1.7
Value41 · Δ7d -0.0
Sentiment71 · Δ7d -2.6
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -2.6.
Contradictions & invalidation
- • Clinical readout risk is dominant because DENALI Part 2 remains the main binary value event for azenosertib.
- • Execution risk persists around ASPENOVA enrollment, trial operations, and companion-diagnostic/commercial preparedness ahead of any potential launch [#SEC-8K-2026-05-12].
- • The bear case is that ZNTL remains essentially a single-asset, binary clinical story where the year-end 2026 DENALI outcome and FDA feedback dominate valuation; if efficacy, safety, enrollment, or regulatory alignment disappoints, downside could be severe despite adequate near-term cash [#SEC-8K-2026-05-12][#SEC-8K-2026-03-26].
Catalyst clock
2026-09-30
Cash runway limits immediate financing pressure
Lead driver: Sentiment · See AI snapshot
Momentum
10
9% active weight
Current posture
7d trendFlat
Δ7d
-1.7
Δ21d
-38.7
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
71
62% active weight
Current posture
7d trendSoftening
Δ7d
-2.6
Δ21d
-16.7
Why this grade
Composite grade C. Momentum 10.1 / Value 41.2 / Sentiment 70.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-18. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-06-18 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.80
Analysis reference price unavailable
Analysis 2026-06-18 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$265.54M
Beta
1.71
Shares Out
71.67M
P/E (TTM) · Derived
-1.9
P/S (TTM)
3.68
P/FCF (TTM) · Derived
-2.06
Rev YoY
-100.0%
EPS YoY
+58.8%
Gross Margin
+96.7%
Op Margin
-615.2%
Net Debt
-$206.32M
Current Ratio
4.82
As of 2026-09-08 • Updated nightlySource: Internal modelMethods & Data